Literature DB >> 25732723

Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity.

Mathilda L Bongers1, Dirk de Ruysscher2,3, Cary Oberije3, Philippe Lambin3, Carin A Uyl-de Groot1,4, V M H Coupé1.   

Abstract

With the shift toward individualized treatment, cost-effectiveness models need to incorporate patient and tumor characteristics that may be relevant to treatment planning. In this study, we used multistate statistical modeling to inform a microsimulation model for cost-effectiveness analysis of individualized radiotherapy in lung cancer. The model tracks clinical events over time and takes patient and tumor features into account. Four clinical states were included in the model: alive without progression, local recurrence, metastasis, and death. Individual patients were simulated by repeatedly sampling a patient profile, consisting of patient and tumor characteristics. The transitioning of patients between the health states is governed by personalized time-dependent hazard rates, which were obtained from multistate statistical modeling (MSSM). The model simulations for both the individualized and conventional radiotherapy strategies demonstrated internal and external validity. Therefore, MSSM is a useful technique for obtaining the correlated individualized transition rates that are required for the quantification of a microsimulation model. Moreover, we have used the hazard ratios, their 95% confidence intervals, and their covariance to quantify the parameter uncertainty of the model in a correlated way. The obtained model will be used to evaluate the cost-effectiveness of individualized radiotherapy treatment planning, including the uncertainty of input parameters. We discuss the model-building process and the strengths and weaknesses of using MSSM in a microsimulation model for individualized radiotherapy in lung cancer.
© The Author(s) 2015.

Entities:  

Keywords:  decision making; multi-state modeling; patient heterogeneity; survival analysis; uncertainty

Mesh:

Year:  2015        PMID: 25732723      PMCID: PMC5134640          DOI: 10.1177/0272989X15574500

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  23 in total

1.  Comparison of Bayesian network and support vector machine models for two-year survival prediction in lung cancer patients treated with radiotherapy.

Authors:  K Jayasurya; G Fung; S Yu; C Dehing-Oberije; D De Ruysscher; A Hope; W De Neve; Y Lievens; P Lambin; A L A J Dekker
Journal:  Med Phys       Date:  2010-04       Impact factor: 4.071

2.  Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).

Authors:  Cary Dehing-Oberije; Hugo Aerts; Shipeng Yu; Dirk De Ruysscher; Paul Menheere; Mika Hilvo; Hiska van der Weide; Bharat Rao; Philippe Lambin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

3.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

4.  Estimation and prediction in a multi-state model for breast cancer.

Authors:  Hein Putter; Jos van der Hage; Geertruida H de Bock; Rachid Elgalta; Cornelis J H van de Velde
Journal:  Biom J       Date:  2006-06       Impact factor: 2.207

Review 5.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

6.  The importance of patient characteristics for the prediction of radiation-induced lung toxicity.

Authors:  Cary Dehing-Oberije; Dirk De Ruysscher; Angela van Baardwijk; Shipeng Yu; Bharat Rao; Philippe Lambin
Journal:  Radiother Oncol       Date:  2009-01-13       Impact factor: 6.280

7.  Multi-state models for the analysis of time-to-event data.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez; Per K Andersen
Journal:  Stat Methods Med Res       Date:  2008-06-18       Impact factor: 3.021

8.  Individualized positron emission tomography-based isotoxic accelerated radiation therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation.

Authors:  Mathilda L Bongers; Veerle M H Coupé; Dirk De Ruysscher; Cary Oberije; Philippe Lambin; Carin A Uyl-de Groot; Cornelia A Uyl-de Groot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-03-15       Impact factor: 7.038

9.  Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.

Authors:  Cary Dehing-Oberije; Shipeng Yu; Dirk De Ruysscher; Sabine Meersschout; Karen Van Beek; Yolande Lievens; Jan Van Meerbeeck; Wilfried De Neve; Bharat Rao; Hiska van der Weide; Philippe Lambin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-25       Impact factor: 7.038

10.  Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.

Authors:  Silvy Laporte; Pierre Squifflet; Noémie Baroux; Frank Fossella; Vassilis Georgoulias; Jean-Louis Pujol; Jean-Yves Douillard; Shinzohy Kudoh; Jean-Pierre Pignon; Emmanuel Quinaux; Marc Buyse
Journal:  BMJ Open       Date:  2013-03-13       Impact factor: 2.692

View more
  2 in total

1.  Analysis of Trends and Factors in Breast Multiple Primary Malignant Neoplasms.

Authors:  Igor Motuzyuk; Oleg Sydorchuk; Natalia Kovtun; Zinaida Palian; Yevhenii Kostiuchenko
Journal:  Breast Cancer (Auckl)       Date:  2018-02-28

2.  Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.

Authors:  Claire Williams; James D Lewsey; Daniel F Mackay; Andrew H Briggs
Journal:  Med Decis Making       Date:  2016-10-04       Impact factor: 2.583

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.